Polaris Capital Group

Polaris Group is a clinical-stage biopharmaceutical company primarily focused on the development of metabolic therapies for cancer. The company's lead drug candidate, ADI-PEG 20 (pegargiminase), is a first-in-class enzyme therapy designed to treat tumors that are arginine-auxotrophic, meaning they lack the ability to synthesize arginine internally. By depleting the external supply of arginine in the bloodstream, ADI-PEG 20 effectively starves these cancer cells while leaving normal cells unaffected. Polaris is currently advancing ADI-PEG 20 through late-stage clinical trials, including a pivotal Phase 3 study for malignant pleural mesothelioma. In addition to its drug development pipeline, the company operates vertically integrated cGMP manufacturing facilities in the United States, allowing it to support global clinical development and offer CDMO services.